您要查找的是不是：
- Micodose heparin 肝素
- Heparin is the treatment of choice. 肝素为首选的治疗剂。
- Human heparin sulphate protoglycans，HSPG Elisa ... 人硫酸肝素糖蛋白（HSPG）试剂盒；
- Heparin is not intended for intramuscular use. 肝素是不打算肌肉注射使用。
- Using micodose of heparin is benefical to terminate the progress of DIC caused by Tsutsugamushi, decrease the rate of MOF and death,shorten the time of rescuing and improve hemoperfusion of organ. 小剂量肝素有利于终止恙虫病急性弥散性血管内凝血的病理进程、改善器官血流灌注,降低器官功能衰竭发生率、死亡率,缩短治愈时间。
- Heparin is the most widely used and reliable anticoagulant. 肝素为最广泛应用及最可靠的抗凝剂。
- To discuss the nursing maneuver of hemodialysis without heparin. 目的探讨无肝素血液透析的护理策略。
- Baxter accounts for about half the U.S. supply of heparin. 巴克斯证实大约一半肝磷脂由美国供应。
- Exceptio include phenytoin, theophylline, and heparin. 只有苯妥英、茶碱和肝素是例外。
- Exceptions include phenytoin, theophylline, and heparin. 只有苯妥英、茶碱和肝素是例外。
- All cases received heparin and urokinase perioperatively. 围手术期抗凝治疗。
- The results suggest that heparin could interrupt AGE clearance... 低分子量肝素对AGE受体无封闭作用。
- Heparin-induced thrombocytopenia occurring after discontinuation of heparin. 肝素停药后发生的肝素相关性血小板减少。
- Serum phosphate levels were elevated throughout the heparin calcium therapy. 整个肝素钙治疗过程中，患者的血磷水平都升高。
- The penetration rates of MPS were between 6 and 50 times of those of heparin. MPS（多磺酸粘多糖）的透皮吸率是肝素的6－50倍。
- Conclusion Heparin could make PLT and MPV decreased, especially in UFH group. 结论肝素抗凝可致PLT及MPV下降,UFH尤其显著;
- Objective: To discuss the nursing maneuver of hemodialysis without heparin. 目的探讨无肝素血液透析的护理策略。
- The heparin plant in China has not been accused of providing a harmful product. 中国的肝磷脂工厂没有被指责提供有害的产品。
- As with most medications, heparin has a significant side effect profile. 正如大部份的药品一样，它也有一些重要的副作用。
- Heparin Sodium Injection, USP is not a catheter lock-flush solution product. 肝素钠注射液，美国药典不是导管锁定冲水解决方案的产品。
